Adcendo licenses rights to Multitude’s ADC targeting tissue factor
Aug. 20, 2024
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.